Na Su

机构：Nanchang University, Shandong University, First Affiliated Hospital of Jiangxi Medical College · ORCID：0000-0003-0499-720X

发表论文 71 篇 · 总被引 844 次 · h-index 17

代表论文

• Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51 (2023 · Nature Communications · 被引 35)
• Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials (2023 · Frontiers in Pharmacology · 被引 32)
• Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis (2023 · Frontiers in Pharmacology · 被引 25)
• Exosome from adipose-derived mesenchymal stem cells attenuates scar formation through microRNA-181a/SIRT1 axis (2023 · Archives of Biochemistry and Biophysics · 被引 20)
• Pharmacological inhibition of LSD1 suppresses growth of hepatocellular carcinoma by inducing GADD45B (2023 · MedComm · 被引 17)
• Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis (2022 · Frontiers in Pharmacology · 被引 17)